https://en.bioecon.ru/capabilities/therapeutics/Recent content in Therapeutics on BioeconHugoen-USTue, 18 Aug 2026 22:19:08 +0700https://en.bioecon.ru/technology/antibiotics-new-gen-anti-amr/Sat, 08 Aug 2026 00:00:00 +0000https://en.bioecon.ru/technology/antibiotics-new-gen-anti-amr/Next-generation antimicrobial compounds and beta-lactamase-inhibitor combinations designed to overcome multi-drug-resistant bacterial infections — a field with real recent approvals but where even a scientifically sound candidate can stall for years on manufacturing paperwork, not efficacy.https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/Sat, 08 Aug 2026 00:00:00 +0000https://en.bioecon.ru/technology/antibody-drug-conjugates-adcs/A monoclonal antibody chemically linked to a highly potent cytotoxic payload, delivering chemotherapy-grade cell killing selectively to antigen-expressing tumor cells — one of oncology’s clearest recent commercial successes, and also a field where a Phase 3 win on efficacy can still surface a real mortality signal.https://en.bioecon.ru/technology/bacteriophage-therapy/Sat, 08 Aug 2026 00:00:00 +0000https://en.bioecon.ru/technology/bacteriophage-therapy/Naturally occurring or precision-engineered bacterial viruses that selectively lyse a target pathogen without disrupting the rest of the microbiome — a genuine answer to antimicrobial resistance still working through the clinical-trial design problems that have already bankrupted one European pioneer.https://en.bioecon.ru/technology/chemoenzymatic-api-synthesis/Mon, 20 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/chemoenzymatic-api-synthesis/Engineered-enzyme steps (transaminases, ketoreductases, lipases) substituted into small-molecule API routes to replace metal-catalysed or multi-step chemical sequences — anchored by Codexis’s CodeEvolver platform (the Merck sitagliptin transaminase case) in the US, Almac’s biocatalysis CDMO in the UK, Lonza’s HPAPI/biocatalysis toolkit in Switzerland, and Asymchem and WuXi AppTec’s biocatalysis-enabled CDMO platforms in China.https://en.bioecon.ru/technology/biosynthetic-steroids/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/biosynthetic-steroids/Corticosteroid and reproductive-hormone APIs made by mycobacterial fermentation of phytosterol into AD/ADD/9-OHAD precursors, then biocatalytic and semi-synthetic finishing — a globally-offshored manufacturing tier anchored by Olon, Farmabios and Gadea in Europe, Tianjin Tianyao in China, Symbiotec in India and Asymchem’s biocatalysis CDMO.https://en.bioecon.ru/technology/bispecific-antibodies/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/bispecific-antibodies/Engineered antibodies that bind two (or more) antigens on one molecule — most powerfully a CD3 arm that recruits the patient’s own T cells to a tumour cell — delivered off-the-shelf as approved drugs across lymphoma and myeloma by Roche, Janssen, Regeneron, AbbVie/Genmab and BeiGene.https://en.bioecon.ru/technology/nucleic-acid-therapeutics/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/nucleic-acid-therapeutics/Short synthetic oligonucleotides — siRNA and antisense — bind a target messenger RNA to silence or reprogram a disease gene, enabled by GalNAc liver targeting and sugar/backbone chemistries, with multiple approved drugs across rare, neurological and cardiometabolic disease.https://en.bioecon.ru/technology/protacs/Sat, 11 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/protacs/Bifunctional small molecules that recruit an E3 ubiquitin ligase to a disease protein, tagging it for proteasomal destruction — an event-driven, catalytic drug modality approaching its first approval with Arvinas’s estrogen-receptor degrader vepdegestrant, and a deep pipeline across IRAK4, IKZF and BTK targets.https://en.bioecon.ru/technology/drug-vaccine-development/Sun, 05 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/drug-vaccine-development/The end-to-end R&D pipeline that carries a drug or vaccine candidate from target identification through Phase I-IV clinical trials to regulatory approval — a 7-15-year, billion-dollar process now being reshaped by personalized mRNA platforms, GLP-1 blockbuster economics and competing FDA, EMA and NMPA regulatory-acceleration reforms.https://en.bioecon.ru/technology/psychedelic-medicine-neuropsychiatric-biologics/Sat, 04 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/psychedelic-medicine-neuropsychiatric-biologics/Psychoactive-compound therapies (psilocybin, MDMA, 5-MeO-DMT) and next-generation non-hallucinogenic psychoplastogens that trigger rapid synaptogenesis via serotonin 5-HT2A receptor signaling, targeting treatment-resistant depression and PTSD — a field with genuine 2026 clinical wins and a high-profile FDA regulatory setback.https://en.bioecon.ru/technology/radiopharmaceuticals-theranostics/Fri, 03 Jul 2026 00:00:00 +0000https://en.bioecon.ru/technology/radiopharmaceuticals-theranostics/Radioactive compounds that pair a tumor-targeting vector with a diagnostic or therapeutic isotope — ‘see what you treat, treat what you see’ — now commercial at multi-hundred-million-dollar manufacturing scale.https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/Wed, 24 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/biopharmaceuticals-biomedicines/Large-molecule therapeutics manufactured via living cells to treat complex diseases like cancer, diabetes, and autoimmune disorders.https://en.bioecon.ru/technology/biologics/Thu, 18 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/biologics/Biologics — monoclonal antibodies, ADCs, CAR-T and gene therapy — are the largest and fastest-growing drug class, built on a reproducible cell-line platform at 2–10 g/L titers.https://en.bioecon.ru/technology/mrna-platforms-lnp-delivery/Thu, 18 Jun 2026 00:00:00 +0000https://en.bioecon.ru/technology/mrna-platforms-lnp-delivery/Synthetic mRNA in lipid nanoparticles (60–100 nm) turns the cell into a bioreactor — from a vaccine platform to personalised cancer immunotherapy and in-vivo protein expression.